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Abstract: Glioblastoma multiforme (GBM) is one of the most lethal primary central nervous
system cancers with a median overall survival of only 12–15 months. The best documented
treatment is surgical tumor debulking followed by chemoradiation and adjuvant chemotherapy
with temozolomide, but treatment resistance and therefore tumor recurrence, is the usual outcome.
Although advances in molecular subtyping suggests GBM can be classified into four subtypes,
one concern about using the original histology for subsequent treatment decisions is that it only
provides a static snapshot of heterogeneous tumors that may undergo longitudinal changes over time,
especially under selective pressure of ongoing therapy. Liquid biopsies obtained from bodily fluids
like blood and cerebro-spinal fluid (CSF) are less invasive, and more easily repeated than surgery.
However, their deployment for patients with brain cancer is only emerging, and possibly suppressed
clinically due to the ongoing belief that the blood brain barrier prevents the egress of circulating tumor
cells, exosomes, and circulating tumor nucleic acids into the bloodstream. Although brain cancer
liquid biopsy analyses appear indeed challenging, advances have been made and here we evaluate
the current literature on the use of liquid biopsies for detection of clinically relevant biomarkers in
GBM to aid diagnosis and prognostication.
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1. Introduction
Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults,
accounting for 62% of all brain tumors in Australia in 2013 and has a poor prognosis with a five-year
survival of 4.6% and median overall survival (OS) estimates of 12–15 months [1]. GBM can be
classified into two categories: primary (arises de-novo) or secondary (transforms from a previous lower
grade tumor) and although they differ in terms of molecular characterization, treatment strategies
and disease outcome overlap considerably [2]. The current standard of therapy for GBM comprises
surgical resection, adjuvant radiotherapy, and concomitant chemotherapy with the alkylating agent,
temozolomide, then adjuvant temozolomide where feasible [3]. The aggressiveness of GBM is thought
to be due, in large part, to its treatment resistance caused by the presence of oncogenic mutations,
ambiguous surgical margins and the blood-brain barrier which limits the uptake, and hence efficacy of
systemic therapy [4]. In many cases, the efficacy of treatment is difficult to determine, particularly early
during therapy, because therapy-associated tissue inflammation often resembles the effects of disease
progression under magnetic resonance imaging (MRI); a phenomenon termed pseudoprogression [5].
As a result, determining true progression of disease is challenging, which in turn impacts on timely
responses to treatment failure in patients. This issue has been a particular challenge in clinical trials,
where no reliable surrogate marker is available for overall survival. It is clear that better biomarkers
are needed to aid in the diagnosis and tracking of the clinical course of patients with GBM.
A non-invasive longitudinal approach for the diagnosis, prognostic assessment, molecular
stratification, prediction of treatment response, and assessment of tumor progression is required for
GBM. Circulating biomarkers are an appealing potential solution to this challenge. Circulating tumor
cells (CTCs) and circulating tumor nucleic acids (ctNAs), and the molecular biomarkers that can be
screened from these tumor entities, already served some of these roles in a number of other solid
cancers [6]. In regards to brain cancer, liquid biopsies are challenging as the presence of the blood–brain
barrier (BBB) impedes the release of tumor entities into the blood stream. The integrity of the BBB may
however be compromised especially in advanced GBM. Although, for a long time, BBB was thought
to prevent the release of CTCs and potentially ctNAs into the blood stream, recent studies showed
that CTCs could be detected in patients with high-grade (WHO grade III and IV) brain cancers [7].
Other studies have also demonstrated that ctDNA and ctRNA can be detected in plasma from GBM
patients as detailed below [8].
In patients with GBM, the lack of readily accessible tumor samples in some patients, and the
lack of repeated debulking benefit in others, means simpler methods of assessing biomarkers from
non-surgical samples warrant closer investigation. Here, we review potential biomarkers that may be
relevant for GBM patient management, and whether they can be detected via liquid biopsies.
2. Molecular Biomarkers in Brain Cancer
A range of molecular biomarkers are associated with prognosis and may potentially stratify
patients for different treatment strategies [9]. Key biomarkers for stratifying patients include IDH1
mutation, MGMT methylation, EGFRvIII mutation and/or EGFR amplification, GFAP mutation,
hTERT promoter alterations, and loss of heterozygosity in chromosome 10 (LOH) (see Table 1). All of
these biomarkers have been detected in CTC or ctNA assays.
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Table 1. Brain cancer biomarkers and detection in liquid biopsies.
Marker Clinical Utility inBrain Cancer
Detected in Brain Cancer
Circulating Tumor Cells (CTCs)
Detected in Brain
Cancer ctNAs Detected in CTCs or ctNAs #
GFAP Yes [10] Yes [11] No No
MGMT * Yes [12] No Yes + [13] Yes, colorectal cancer [14]
IDH1 Yes [15] No Yes + [16] Yes, leukaemia [17]
EGFR ** Emerging [18] No Yes + [19] Yes, lung cancer [20,21]
hTERT Emerging [22] Yes [7] Yes + [23] Yes, Urothelial cancer [24],Metastatic breast cancer [25]
LOH chr10 Yes [26] No Yes + [8] Yes, Ovarian cancer [27]
LOH chr10 loss of heterozygocity chromosome 10; # in other cancers; * MGMT promoter methylation; ** EGFR
mutations including variant III; + plasma derived circulatory tumour nucleic acids (ctNA).
2.1. Glial Fibrillary Acidic Protein (GFAP)
Glial fibrillary acidic protein (GFAP), an intermediate filament protein expressed by astrocytes and
other central nervous cells is detected at significantly higher levels in GBM tissue compared to other
intracranial lesions [10]. However, GFAP in serum cannot be used as a specific diagnostic measure for
GBM due to the ‘sensitivity gap’ caused by heterogeneous/low expression of GFAP on some tumors
that leads to the undetectable levels of GFAP released into the blood stream [28]. Higher serum GFAP
levels correlate with tumor volumes, intra-tumoral GFAP expression, and extent of necrosis [28,29].
Serum GFAP levels associated with primary and recurrent high-grade glioma (HGG) tumor volumes
and short PFS progression free survival (PFS). Higher preoperative GFAP serum levels also correlated
with increased tumor volume and necrosis [30]. Furthermore, serum GFAP levels are associated with
IDH1 mutational status (an established prognostic marker discussed below), with significantly lower
serum GFAP found in IDH1 mutated HGGs [30]. GFAP is currently the most prevalent marker for the
identification of GBM CTCs and expression is frequently maintained in GBM, despite its heterogeneity.
2.2. Methylguanine-DNA Methyltransferase Promoter Methylation (MGMT)
The O-6 methylguanine-DNA methyltransferase (MGMT) protein is involved in DNA repair,
by reversing DNA alkylation [12]. Consequently, MGMT expression is linked to resistance to DNA
alkylating agents, such as temozolamide, the main chemotherapeutic agent used for GBM [12]. Reduced
MGMT expression, commonly caused by MGMT promoter methylation, renders cells more susceptible
to temozolamide [31]. MGMT promoter methylation is more common in secondary GBM (75%)
compared to primary GBM (26%) [32], and is associated with longer OS and PFS in patients treated
with temozolamide and standard dose of radiotherapy (median OS of 22–26 months vs. 12–15 months
in non-MGMT methylated tumors). Since temozolamide has toxicities, especially in patients with
pre-existing comorbidities, detection of MGMT promoter methylation status may help tailor the best
temozolamide dosage or schedule for the patient [31,33]. MGMT promoter methylation has been
detected in plasma ctDNA of glioma patients, and methylation status correlated with GBM tissue,
suggesting that liquid biopsy material could have potential in detecting MGMT promoter methylation
status [13].
2.3. Isocitrate Dehydrogenase Mutations (IDH1/2)
Isocitrate dehydrogenase 1 and 2 (IDH1/2) enzymes catalyze the reversible oxidation of isocitrate
to yield α-ketoglutarate with simultaneous reduction of NADP+ to NADPH. NADPH provides a
cellular defense against intracellular oxidative damage [34,35]. The chemo-sensitivity of mutant
IDH1 tumors is attributed to the impairment of DNA repair function resulting in increased DNA
damage inducing apoptotic cell death [36]. About 12% of GBM patients carry mutations in IDH1 or
IDH2; 90% of those carrying an IDH1 mutation have the specific R132H change, a missense mutation
switching the amino acid arginine to histidine at position 132. The most common IDH2 mutation is
IDH2-R172H [37].
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IDH1 mutation rate reported in secondary GBM is 73–85%, whereas its rarely present in primary
GBM [15,32,38]. IDH-mutant status is associated with longer OS in patients with WHO grade II-IV
glioma. However, the association of higher rates of total surgical resections in IDH1 mutated malignant
astrocytoma due to the clinical factors such as younger age, frontal location, and a non-enhancing
disease component in the tumor mass may also contribute to better OS [39]. In vitro studies have
shown that IDH1 mutant cells are more sensitive to radiation therapy as compared to wild type
cells and low grade and secondary IDH1 mutant gliomas show increased chemosensitivity [40–42].
IDH mutations are therefore considered a positive prognostic marker for survival in grade II to IV
gliomas [43].
IDH1 mutation detection was confirmed in plasma ctDNA of 80 glioma patients with 100%
specificity and 60% sensitivity [16]. IDH1 mutations can be detected using various techniques such
as pyrosequencing, immunohistochemistry and droplet digital polymerase chain reaction (ddPCR).
ddPCR detection of the IDH1-R132H mutation is highly sensitive and suited for single cells and ctDNA
analysis [44].
2.4. Epidermal Growth Factor Receptor (EGFR)
Epidermal growth factor receptor (EGFR) is a potential GBM biomarker. In normal cells,
EGFR is involved in growth factor signaling, while cancer-associated oncogenic changes (mutations,
overexpression, variant expression) often confer ligand independent oncogenic activity [45]. In brain
cancer, one of the most widely investigated EGFR alterations is the EGFR transcript variant III
(EGFRvIII), caused by varying DNA deletions in the gene that all affect mRNA splicing to exclude
exons 2–7 [19]. Up to 33% of GBM express EGFRvIII, which has been associated with decreased survival,
particularly in adolescents [19,46,47]. EGFRvIII is implicated in the process of gliomagenesis and in
conferring resistance to chemotherapy [48]. Despite its proposed role in tumorigenesis, the prognostic
significance of this mutant is still controversial. EGFRvIII overexpression in the presence of EGFR
amplification was proposed as the strongest indicator of poor prognosis and survival [47]. In contrast,
other studies suggest that EGFRvIII may be a positive prognostic marker and indicate prolonged
survival of EGFRvIII patients treated with surgery and chemo/radiation therapy [49,50]. Regardless
of this controversy, due to its prevalence, EGFRvIII detection in a pathological setting can help to
clearly classify GBM. While it may also present a promising therapeutic target for GBM treatment,
EGFR targeting tyrosine kinase inhibitors (TKIs, e.g., gefitinib and erlotinib) have not shown promise
in clinical trials of GBM patients so far, possibly due to the poor penetration of these drugs through
the BBB, thereby limiting the concentration of drug reaching the tumors [51]. Studies have shown
that gliomas lack mutations in the EGFR exons 19–21 encoding the tyrosine kinase domain (common
activating mutations in lung cancer that sensitize those cancers for gefitinib and erlotinib), and may
be less dependent on EGFR kinase activity overall, also contributing to the failure of EGFR-TKIs [51].
Second generation EGFR-TKIs (afatinib and dacomitinib) have shown activity in GBM, but more
studies are needed to confirm clinical utility. The BBB-permeable third generation inhibitor AZD9291
(osimertinib) may be an attractive candidate for EGFR inhibition therapy in GBM. Recent studies
have shown that AZD9291 can significantly inhibit tumor growth and prolong animal survival in an
orthotopic GBM model [52].
In lung cancer patients, EGFR mutations are readily detectable in liquid biopsies as an alternative
to tissue biopsy [21]. While there are fewer such studies in brain cancer, DNA deletions causing
EGFRvIII expression were detected in ctDNA of three of thirteen GBM patients in one study [19].
In this study, the exact deletions were first determined from matching tumor tissue genomic DNA
by long range PCR, then primers adjacent to the deletions were generated to confirm presence in
ctDNA. Thus, although, long range PCR assay is not useful for ctDNA, which has an average length
of only 170 bases [19], the study confirmed detectability in ctDNA and confirmed the association of
ctDNA amount with disease status (degree of total resection). As the exact deletions vary; detection
assays from ctRNA would need to be further developed for routine EGFRvIII testing. Alternatively,
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an optimized GBM CTC enrichment protocol may allow to successfully detect EGFRvIII transcripts in
CTC samples, comparable to androgen receptor variant 7 (AR-V7) analysis in prostate cancer [53].
2.5. Telomerase Promoter Mutations (TERT)
Telomerase reverse transcriptase (TERT) is a ribonucleoprotein enzyme essential for the replication
of telomeres, the chromosome termini. Telomeres contain repetitive DNA sequences that become
progressively shorter during successive cell divisions, ultimately leading to a permanent proliferative
arrest. Telomerase is the main enzyme that counteracts telomere shortening through cell division and
is normally only expressed in stem cells and gametes, but it is also central to cell transformation and
immortalization during cancer development [54,55].
Two specific point mutations in the promoter of TERT (pTERT), C228T, and C250T (numeration
relating to ATG start codon), have been identified in cancer cells and are proposed to activate
telomerase [56]. These promoter mutations appear mutually exclusive [57]. pTERT mutations are
common in many cancers and have been found in various cancers including GBM while not found
in normal cells [54,56,58–61]. A high percentage of GBM samples (80–90%), have pTERT mutations
correlated with increased TERT gene protein and accumulation. Patients with pTERT mutations had
shorter OS than those without, 11 vs. 20 months, respectively [57,59,62,63].
pTERT mutations have previously been detected in liquid biopsy of patients with other cancers,
and due its high prevalence, pTERT mutations detected from liquid biopsy would be predicted to be
feasible in GBM patients and detection could contribute to future diagnostic assays [61,64].
2.6. Loss of Heterozygosity
Loss of heterozygosity (LOH) is the loss of genetic material from one of the two alleles of certain
genes and is a frequently occurring genetic event in glioblastomas. LOH of 10q is found in both primary
and secondary GBM occurring at the frequencies of 60–80% [2]. Complete loss of chromosome 10 has
been exclusively associated with primary GBM [26]. The three commonly deleted loci on chromosome
10 are 10q14-p15, 10q23-24 (PTEN) and 10q25-pter [26]. The most important loss among these three
is the loss of tumor suppressor gene PTEN along with other genes including DMBT1, MXI1, LGI1,
WDRI1, and FGFR2. The PTEN protein is a phosphatase that plays an important role in inhibiting the
PI3K/AKT/mTOR pathway. PTEN mutations or loss favor tumor development and loss of the PTEN
loci 10q25-pter is associated with the progression of low-grade brain tumor and anaplastic astrocytoma
to high grade glioblastomas.
LOH on chromosome 22 has also been found in GBM. The most frequent loss is that of chromosome
22q, which is found in 82% of secondary GBM and 41% of primary GBM. Deletion of the locus 22q12.3
leads to loss of the tumor suppressor gene TIMP-3, encoding the tissue inhibitor of metalloproteinases-3
(TIMP-3) [65]. TIMP-3 induces apoptosis and inhibits tumor cell growth and cancer progression.
Chromosome 19q LOH is more frequently detected in secondary GBM (54%) than primary GBM (6%).
LOH on chromosome 1 is often associated with longer survival but is a rare genetic event in both
primary (12%) and secondary GBM (15%) [66]. Studies have also shown that LOH of 1p in combination
with 19q is significantly associated with longer overall survival in glioblastoma patients [66,67].
LOH have been detected in the ctDNA of patients suffering from gliomas and other cancers [8,27].
Highly sensitive assays should be designed for the detection of LOH from liquid biopsies to facilitate
the diagnosis and molecular subtyping of gliomas.
3. Liquid Biopsies
Liquid biopsies are known to carry a variety of entities, other than cells and DNA, shed by primary
or metastatic lesions. In brain cancer, the main liquid biopsies that may be analyzed for tumor-specific
biomarkers are blood and cerebro-spinal fluid (CSF) (Figure 1).
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Figure 1. Comparison of tissue and liquid biopsies.
The schematic indicates benefits (green) and limitations (red) of (a) tissue biopsy vs. (b) liquid
biopsies: cerebro-spinal fluid (CSF) and blood. A variety of entities including CTCs, ctNAs, exosomes,
microRNA, proteins (proteomics), lipids (lipidomics), and metabolized products (metabolome) are
available for analysis.
3.1. Circulating Tumor Cells (CTCs)
Circulating tumor cells (CTCs) are cells shed from primary or metastatic tumors into the blood
stream [68]. CTCs are validated prognostic biomarkers for a variety of cancers such as lung, melanoma,
osteosarcoma, pheochromocytoma, and parathyroid [69]. Importantly, CTCs can be a surrogate
of tumor tissue and analyzed for the presence of molecular biomarkers [70]. The most commonly
employed CTC detection methods rely on the presence of epithelial cell adhesion molecule (EpCAM),
which is expressed on most carcinoma cell surfaces, but not on GBM cells [71]. Consequently,
other strategies have been employed to detect GBM CTCs. Currently, a limited number of studies have
detected CTCs in 21–82% of GBM patients by applying different methods for CTC enrichment and
identification (see Table 2).
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Table 2. CTC detection in glioblastoma multiforme (GBM) patient blood.
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Small cohort size, requires viral





for glial fibrillary acidic protein
(GFAP) [11]
141 0.1–2.2 20.6% (29/141) EGFR amplification No correlation with OS
GFAP heterogeneous in GBM,
use as sole ID marker may
under-estimate CTC counts
CTC-ichip leucocytes depletion, CTC ID
with probing for SOX2, Tubulin b-3,
EGFR, A2B5 and c-MET [72]
33 11.8 (progressive disease)2.1 (stable disease) 39% (13/33) N/A
Prognostic marker (progressive




(chromosome 8 polyploidy) and
exclusion of CD45+ cells [69]
31 0.13–1.33 71% (24/31) N/A
CTC count decreases post
adjuvant therapy, CTCs may
help distinguish radio-necrosis
from true tumor progression
Small cohort size
Parsortix platform for size based CTC
capture, CTC ID testing by EGFR, Ki67,
EB1 probing [73]




N/A Small cohort size
VAR2CSA malaria protein based
targeted immunomagnetic isolation [74] 5 (GBM) 3.5~ 80% (4/5)
NGS: IDHI, RB1, ALK,
LOH 1p/19q, MGMT N/A
Small cohort size, use of
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and ID may reduce specificity
of CTC detection
MCAM, MCSP targeted
immunomagnetic isolation, GFAP and
GLAST probing [75]
13 (15 samples) 1.5 60% (9/15) N/A No correlation of CTC countswith PFS/OS Small cohort size
ID CTC identification, # Average CTC counts detected normalised per 1 mL blood; * proportion of CTC positive patients; RT radiotherapy; N/A not applicable; ~estimated from graph
in [74] for 5 GBM patients.
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Studies demonstrate that GBM CTCs have a high mesenchymal and low pro-neural signature,
with elevated EGFR copy number and chromosome alterations (gain of chromosomes 3, 7, and 12;
and loss of 10, 13, and 22) comparable with their primary tumors. Mutational analysis of GBM
CTCs using next generation sequencing (NGS) or more sensitive targeted approaches may help to
stratify patient with high risk of relapse and direct treatment strategies [70,76]. Thus, CTC analysis
may facilitate molecular subtyping of GBM, and as such may serve as prognostic and predictive
biomarkers. Furthermore, the mesenchymal transcript expression in GBM CTCs suggests that a
process similar to epithelial to mesenchymal transition (EMT) might modulate GBM homeostasis and
dissemination. Therefore, CTC evaluation may provide unique biological insights into the relatively
unknown pathogenesis and pathophysiology of GBM. Moreover, CTC monitoring may have the
capacity to differentiate between tumor recurrence and pseudo-progression. There is some evidence
that CTC counts reflect disease status, increasing with progression and falling in in response to
chemo-radiotherapy [69]. Hence, CTC analysis could potentially complement conventional MRI to
monitor GBM disease course.
Although CTCs have significant potential in their application to GBM, implementation into the
clinical setting has a number of challenges. Firstly, CTC isolation from GBM patients appear to be
limited by low CTC flux and method complexity [69]. Secondly, due to the heterogeneity of GBM,
the information gained from the molecular subtyping and characterization of rare, individual CTCs
may not be adequately representative of a patient’s entire GBM [71]. Thirdly, so far reports comprise
small patient cohort sizes with no long-term data and challenging interpretations of any association
with clinical outcomes to date [11]. Fourthly, it is worth considering that CTCs may have a limited role
in monitoring the efficacy of the antiangiogenic agent bevacizumab, a standard systemic treatment
used in GBM. As bevacizumab stabilizes the BBB, it may potentially mitigate the propagation of CTCs
into systemic circulation and produce false negative results [71]; although better understanding of
how CTCs traverse the BBB is needed. Finally, the question as to why GBM only rarely metastasizes,
despite up to 82% patients carrying CTCs, remains to be answered.
3.2. Circulating Tumor Nucleic Acids (ctNAs)
Circulating tumor DNA and RNA (ctDNA and ctRNA, respectively, or ctNA in combination)
are released into the bloodstream by breakdown of cancer tissue [77]. To analyze ctNA, the key
challenge is to separate the signal from the noise by developing highly sensitive and specific methods
to identify low concentrations of ctNA against the high background amounts of cell free DNA and
RNA in the blood originating from normal cell homeostasis. Typically, this is achieved by detection of
tumor-specific biomarkers, such as mutations like IDH1-R132H in GBM. In solid tumors, such as lung
cancer, ctNA is more readily detected in patients with a higher tumor burden, and have been shown to
be an early predictor of response to systemic treatment [21].
ctNA has been detected in patients with primary brain cancers including astrocytic (41) or
oligodendroglial tumors (29). All oligodendroglial tumors and 80.5% of astrocytic tumors showed
detectable biomarkers (MGMT promoter methylation and/or 10q LOH and/or 1p/19q LOH) in serum
ctDNA in one study [8]. Serum ctDNA was used to detect methylation status of certain genes
(MGMT, RASSF1A, CDKN2b, and CDKN2a) associated with the pathogenesis of CNS cancers in
a cohort of 33 brain cancer patients (7 primary or recurrent GBM, 8 astrocytomas, 2 gliosarcoma,
6 meningiomas, and 10 other metastatic CNS cancer). Seventy percent of patients from glial tumor
group had ctDNA-detectable promotor methylation of at least one gene. Similarly, at least one
promotor was methylated in 7/10 patients of metastatic group and 3/6 patients who suffered from
meningiomas [78]. As described above, various biomarkers relevant for GBM (IDH1, MGMT, GFAP,
hTERT) are detectable in ctDNA from brain cancer patients, suggesting that the BBB does not effectively
prevent its release into the blood. Nevertheless, there are challenges with the detection of ctDNA in
GBM patient blood since concentrations of detected ctDNA is generally lower, and the proportion of
ctDNA positive patients are less, compared to other cancers [79]. Highly sensitive techniques such
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as droplet digital PCR (ddPCR) assays or improved targeted next-generation sequencing (NGS) are
emerging as successful approaches to identify and monitor ctDNA [80]. Since plasma is a readily
accessible source of tumor tissue during a patient’s treatment journey, tracking ctNA changes may be
a key tool to identify temporal molecular changes, improving the personalization of treatments for
patients during different stages of their disease.
3.3. Cerebro-Spinal Fluid
CSF is a highly informative liquid biopsy source in GBM that can be analyzed for biomarker
information. While clearly being more invasive than a peripheral blood draw, and carrying some
risks not tolerated by all patients, it is also a less invasive procedure compared to surgical tissue
biopsies. Longitudinal CSF evaluation during the disease course to monitor the disease progression
may be possible, but patients would have to agree to repeated lumbar punctures. ctDNA can be
isolated from CSF and current data suggest that it is comparably more abundant than plasma-derived
ctDNA [81,82]. High-grade tumors (WHO grade III and IV) are more likely to have detectable ctDNA
in CSF as compared to lower-grade tumors. For instance, 35 out of the 38 patients showed positive
detection for pTERT mutation in their CSF sample with the specificity of 100% and sensitivity of
92.1% [23]. Not surprisingly, the sensitivity was much lower (7.9%) in matched plasma derived
ctDNA samples, suggesting CSF is a superior liquid biopsy for detection of biomarkers. Critically,
the study established significant correlation between the mutant allele frequency and disease burden
and association with OS [23]; CSF ctDNA may thus be a prognostic marker. In another study, a custom
FDA-authorized next generation sequencing assay was used to analyze the tumors of 85 GBM patients
(WHO grade IV GBM: 46, grade III: 26, grade II: 13). For 49.4% (42/85) at least one tumor-derived
genetic alteration was detected in CSF. For 20 patients, matched tissue biopsies and CSF was analyzed
and all pairs shared mutations. CSF ctDNA also revealed copy number alterations (CNAs), promoter
mutations, protein-coding mutations, and structural rearrangements correlating with poor survival
rates, despite lack of association between ctDNA detection and tumor grade, disease duration, or prior
therapy [82]. A study in primary lung cancer patients with secondary brain metastases supports the
notion of CSF as a viable liquid biopsy source, as it compared NGS results from CSF ctDNA with
plasma ctDNA and CTCs to find the mutation patterns of driver genes. The mutation detection rate
was found to be 95.2% (20/21), 66.7% (14/21), and 39% (8/21) in CSF ctDNA, plasma ctDNA and CTCs,
respectively. EGFR mutations were detected in 12 (57.1%) of patients via CSF as compared to only
5 patients in plasma ctDNA and blood-derived CTCs. EGFR mutation status of CSF-ctDNA was
concordant with the EGFR mutation status of primary tumor in 88.9% (16/18) of patients [83].
Taken together, CSF may be a more reliable surrogate tumor source for biomarker testing than
plasma, presumably due to its direct contact with the brain. However, while it has some potential
to be used repeatedly and longitudinally to monitor disease progression, it is also more invasive.
The trade-off between invasiveness and clinical acceptability on the one hand, with the accuracy of
the method on the other therefore favors plasma-derived ctDNA as the first line approach. However,
more data are needed to fully compare both sources, and it is possible that both can prove beneficial:
initial mutation screening in CSF may reveal a mutation signature for each patient that later can be
followed up in plasma ctDNA. Reports comparing plasma and CSF-derived ctDNA are summarized
in Table 3.
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Table 3. Comparison of CSF and blood derived ctDNA.
ctDNA Source
(Reference) Patients No Biomarker Tested Percentage Detection # Relevance to Disease
Plasma ctDNA,
CSF ctDNA [81] 12
NGS: EGFR, PTEN, ESR1,
IDH1, ERBB2, FGFR2
“higher” sensitivity of mutation detection
from CSF ctDNA Nd
Plasma ctDNA,
CSF ctDNA [82] 85
NGS: TERT, TP53, IDH1,
EGFR, and EGFRvIII 49.4% vs. 15.7% CSF vs. plasma ctDNA
Prognostic: shorter survival of
CSF ctDNA positive patients
Plasma ctDNA,
CSF ctDNA [23] 38 pTERT mutation 92.1% vs. 7.9% CSF vs. plasma ctDNA
pTERT mutation potential poor
survival predictor
Plasma ctDNA,
CSF ctDNA * [83] 21
NGS: EGFR, KIT, PIK3CA,
TP53, SMAD4, ATM,
SMARCB1, PTEN
95.2% vs. 66.7% CSF vs. plasma ctDNA Nd
Plasma ctDNA,
CSF ctDNA [84] 7
NGS: NF2, AKT, BRAF,
NRAS, EGFR
CSF ctDNA detection “significantly higher”
with low systemic disease burden Nd
* Lung cancer metastasised to brain; # proportion of patients with detected ctDNA; Nd not determined.
3.4. Exosomes
Exosomes are membrane enclosed extra-cellular vesicles (EVs), generally 40–150 nm in diameter,
that are actively released by both healthy cells and cancer cells. They carry various cell components
such as proteins, nucleic acids (mRNA, DNA, non-coding RNA), and lipids. Docking onto other cells,
they can exchange this cargo and thereby alter molecular activities in recipient cells. Exosomes released
by cancer cells can be extracted as non-invasive, circulatory biomarkers that contain molecular
characteristics of the original tumor and can be screened for the detection of these signatures. In one
study, an orthotopic xenotransplant mouse model of human cancer stem cells showed that extracellular
vesicles can cross the intact BBB and reach the bloodstream [85], suggesting that peripheral blood of
both low- and high-grade glioma patients can be used to isolate EVs. These EVs were shown to be
a source for detection of clinically relevant prognostic biomarkers, such as IDH1-R132H, and were
successfully extracted from blood and CSF [85–87]. Higher exosome concentration in plasma of GBM
patients compared to healthy individuals was demonstrated and linked to tumor recurrence in patients
post-resection. Exosomes may be a potential biomarker to distinguish patients with GBM from not
only healthy controls, but also from patients harboring other brain lesions [86,88], and may be helpful
in the early diagnosis of disease [89]. Reports suggest that exosomal miRNA screening could be
used as a predictive biomarker for GBM patients to monitor response to chemotherapy and drug
resistance [90–92]. Further studies on larger cohorts are needed to validate exosome analysis as a
diagnostic and therapeutic tool.
4. Conclusions
There is good emerging evidence that liquid biopsies, such as blood and CSF, can be used as
potential surrogates for tissue biopsy for diagnostic and prognostic biomarker analysis in gliomas.
However, in general, these studies are small, and do not provide sufficient statistical power for firm
conclusions in regard to biomarker detection association with disease parameters. Given the relative
difficulty of obtaining brain tissue, and the challenges associated with monitoring brain cancer and
determining treatment response, improved strategies to develop superior biomarkers are essential.
Liquid biopsies offer a more accessible source of molecular information, which may allow diagnosis
and characterization without invasive surgery. The disrupted BBB, which is a hallmark of GBM,
may offer a window into the biological behavior through the study of liquid biopsies. Despite generally
reduced detection of plasma ctNA in brain cancer, monitoring of disease progression may still be useful
with plasma ctDNA for individual patients, as long as specific tumor-associated mutations are known
for the patient, potentially via initial CSF screening. CTCs where detectable, may give information
regarding novel proteins expressed on cancer cells, such as PD-L1, that may be a prognostic predictor
of OS and may possibly suggest alternative management strategies.
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